MONTELUKAST ( DrugBank: Montelukast )
8 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
6 | パーキンソン病 | 1 |
13 | 多発性硬化症/視神経脊髄炎 | 1 |
46 | 悪性関節リウマチ | 5 |
61 | 自己免疫性溶血性貧血 | 1 |
63 | 特発性血小板減少性紫斑病 | 1 |
85 | 特発性間質性肺炎 | 2 |
98 | 好酸球性消化管疾患 | 4 |
228 | 閉塞性細気管支炎 | 5 |
6. パーキンソン病
臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2020-000148-76-SE (EUCTR) | 04/08/2021 | 25/02/2020 | Effects of the Montelukast drug on brain inflammation in Parkinson's disease. | Effects of Montelukast on neuroinflammation in Parkinson's Disease. An open-label single-center trial. | Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Montelukast Product Name: Montelukast Krka | Stockholm Health Care Services | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 15 | Phase 2 | Sweden |
13. 多発性硬化症/視神経脊髄炎
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02410278 (ClinicalTrials.gov) | March 12, 2015 | 2/4/2015 | Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera | A Multicenter, Double- Blind, Placebo- Controlled Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera® (Dimethyl Fumarate) Delayed Release Capsules | Multiple Sclerosis | Drug: dimethyl fumarate;Drug: montelukast;Drug: Placebo | Biogen | NULL | Completed | 18 Years | N/A | All | 102 | Phase 4 | United States |
46. 悪性関節リウマチ
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05447520 (ClinicalTrials.gov) | July 15, 2022 | 1/7/2022 | Montelukast Use in Rheumatoid Arthritis | Clinical Study Evaluating the Efficacy and Safety of Adjunctive Use of Montelukast in Rheumatoid Arthritis Patients | Rheumatoid Arthritis | Drug: Montelukast;Drug: Placebo;Drug: Conventional DMARDs | Noha Mansour | NULL | Recruiting | 18 Years | 80 Years | All | 50 | Phase 2 | Egypt |
2 | NCT03770923 (ClinicalTrials.gov) | October 1, 2018 | 7/12/2018 | Effect of Some Drugs on Rheumatoid Arithritis Activity | Clinical Study Evaluating the Effect of Histamine 1 Receptor Antagonist and Leukotreine Receptor Antagonist on Patients With Rheumatoid Arithritis | Rheumatoid Arthritis | Drug: Rupatadine;Drug: Montelukast | Sherief Abd-Elsalam | NULL | Recruiting | 18 Years | N/A | All | 75 | Phase 3 | Egypt |
3 | NCT03131973 (ClinicalTrials.gov) | May 13, 2017 | 25/4/2017 | Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin | Effects of Concomitant Administration of BMS-986195 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates for Cytochrome P450 1A2, 2C8, 2C9, 2C19, 3A4, Organic Anion Transporter Polypeptide 1B1 and P-glycoprotein in Healthy Participants | Rheumatoid Arthritis | Drug: BMS-986195;Drug: Methotrexate;Drug: Leucovorin;Drug: Caffeine;Drug: Montelukast;Drug: Flurbiprofen;Drug: Omeprazole;Drug: Midazolam;Drug: Digoxin;Drug: Pravastatin | Bristol-Myers Squibb | NULL | Completed | 18 Years | 50 Years | All | 26 | Phase 1 | United States |
4 | NCT02762123 (ClinicalTrials.gov) | May 2016 | 3/5/2016 | A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates | Effects of Concomitant Administration of BMS-986142 on the Single-dose Pharmacokinetics of Probe Substrates for CYP2C8, CYP2C9, CYP2C19, CYP3A4, and P-gp in Healthy Subjects | Rheumatoid Arthritis | Drug: BMS-986142 200mg;Drug: BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin);Drug: BMS-986142 350mg | Bristol-Myers Squibb | NULL | Completed | 18 Years | 50 Years | Both | 28 | Phase 1 | United States |
5 | NCT02456844 (ClinicalTrials.gov) | May 2015 | 27/5/2015 | Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy Patients | Effects of BMS-986142 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates Montelukast (CYP2C8), Flurbiprofen (CYP2C9), Midazolam (CYP3A4), Digoxin (P-gp), and Pravastatin (OATP1B1) in Healthy Subjects | Rheumatoid Arthritis | Drug: Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142;Drug: Methotrexate, Leucovorin and BMS-986142 | Bristol-Myers Squibb | NULL | Completed | 18 Years | 50 Years | Both | 24 | Phase 1 | NULL |
61. 自己免疫性溶血性貧血
臨床試験数 : 146 / 薬物数 : 131 - (DrugBank : 59) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 158
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2020-003880-24-IT (EUCTR) | 07/06/2021 | 04/06/2021 | Safety, pharmacokinetics, and efficacy of subcutaneous isatuximab in adults with warm autoimmune hemolytic anemia | A multicenter, open-label, non-randomized, Phase 1b/2 study to evaluate the safety, pharmacokinetics,and efficacy of subcutaneous isatuximab in adults with warm autoimmune hemolytic anemia - . | Warm autoimmune hemolytic anemia MedDRA version: 20.0;Level: PT;Classification code 10047822;Term: Warm type haemolytic anaemia;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Product Name: Montelukast Product Code: [.] INN or Proposed INN: MONTELUKAST Product Name: Isatuximab Product Code: [SAR650984] INN or Proposed INN: Isatuximab Product Name: Paracetamolo Product Code: [.] INN or Proposed INN: PARACETAMOLO Product Name: Famotidina Product Code: [.] INN or Proposed INN: FAMOTIDINA Product Name: Levocitirizina Product Code: [.] INN or Proposed INN: LEVOCETIRIZINA DICLORIDRATO | SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 23 | Phase 1;Phase 2 | France;United States;Hungary;Belgium;Netherlands;Germany;United Kingdom;Italy |
63. 特発性血小板減少性紫斑病
臨床試験数 : 391 / 薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR2000039630 | 2021-01-01 | 2020-11-03 | Phase II clinical trial of the superiority of montelukastine in combination with TPO-MPL agonists for the treament of primary immune thrombocytopenia | Phase II clinical trial of the superiority of montelukastine in combination with TPO-MPL agonists for the treament of primary immune thrombocytopenia | Primary immune thrombocytopenia | experimental group:Montelukast sodium 10mg/day; rhTPO 15000 units;control group:rhTPO 15000 units; | Department of Hematology, Second Medical Center, Chinese PLA General Hospital | NULL | Recruiting | 14 | 80 | Both | experimental group:51;control group:51; | Phase 2 | China |
85. 特発性間質性肺炎
臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR-OOC-15005841 | 2015-01-01 | 2015-01-17 | Montelukast Sodium Tablets treatment clinical study for intractable cough by idiopathic pulmonary fibrosis | Montelukast Sodium Tablets treatment clinical study for intractable cough by idiopathic pulmonary fibrosis | Idiopathic pulmonary fibrosis | Montelukast Sodium Tablets treatment group :Montelukast Sodium Tablets: oral, 1 tablets each time (10mg), 1 time a day, at bedtime, for a period of 12 weeks;control group :Don't take Montelukast Sodium Tablets; | Shanghai Pulmonary Hospital | NULL | Recruiting | 50 | 80 | Both | Montelukast Sodium Tablets treatment group :30;control group :30; | NULL | |
2 | NCT01432080 (ClinicalTrials.gov) | September 2011 | 8/9/2011 | Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant | Does Increasing Immunosuppression Prevent Transplant-associated Lung-disease Triggered by Viral Respiratory Tract Infection Following Allogeneic Stem Cell Transplant? A Pilot Study | Respiratory Tract Infections;Bronchiolitis Obliterans;Cryptogenic Organizing Pneumonia;Lung Diseases, Interstitial | Drug: Prednisone;Drug: Azithromycin;Drug: Montelukast;Drug: Symbicort | Maisonneuve-Rosemont Hospital | The Canadian Blood and Marrow Transplant Group | Terminated | 18 Years | N/A | All | 12 | Phase 2 | Canada |
98. 好酸球性消化管疾患
臨床試験数 : 172 / 薬物数 : 149 - (DrugBank : 39) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 135
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01702701 (ClinicalTrials.gov) | January 2012 | 4/10/2012 | Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone | Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone | Eosinophilic Esophagitis;Dysphagia | Drug: Montelukast;Drug: Fluticasone | Medical College of Wisconsin | NULL | Withdrawn | 18 Years | N/A | All | 0 | Phase 3 | United States |
2 | NCT01458418 (ClinicalTrials.gov) | December 2011 | 18/10/2011 | A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children | A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children | Eosinophilic Esophagitis | Drug: Montelukast;Other: placebo;Drug: 5 mg Montelukast | Children's Mercy Hospital Kansas City | NULL | Terminated | 2 Years | 17 Years | All | 4 | N/A | United States |
3 | NCT00511316 (ClinicalTrials.gov) | August 2007 | 1/8/2007 | Trial of Montelukast in Eosinophilic Esophagitis | A Randomized Placebo-Controlled Trial of Montelukast in Maintenance Therapy of Asymptomatic Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: Montelukast/ Singulair;Drug: Placebo | Mayo Clinic | Merck Sharp & Dohme Corp.;Merck Sharp & Dohme Corp. | Completed | 18 Years | 100 Years | Both | 41 | Phase 1 | United States |
4 | NCT00148603 (ClinicalTrials.gov) | September 2005 | 6/9/2005 | Montelukast in the Treatment of Duodenal Eosinophilia | Montelukast in the Treatment of Duodenal Eosinophilia in Children With Dyspepsia: Effect on Eosinophil Density and Activation in Relation to Pharmacokinetics | Eosinophilic Gastroenteritis;Dyspepsia | Drug: montelukast | Children's Mercy Hospital Kansas City | Merck Sharp & Dohme Corp. | Completed | 8 Years | 17 Years | Both | 24 | N/A | United States |
228. 閉塞性細気管支炎
臨床試験数 : 97 / 薬物数 : 118 - (DrugBank : 32) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 156
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01432080 (ClinicalTrials.gov) | September 2011 | 8/9/2011 | Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant | Does Increasing Immunosuppression Prevent Transplant-associated Lung-disease Triggered by Viral Respiratory Tract Infection Following Allogeneic Stem Cell Transplant? A Pilot Study | Respiratory Tract Infections;Bronchiolitis Obliterans;Cryptogenic Organizing Pneumonia;Lung Diseases, Interstitial | Drug: Prednisone;Drug: Azithromycin;Drug: Montelukast;Drug: Symbicort | Maisonneuve-Rosemont Hospital | The Canadian Blood and Marrow Transplant Group | Terminated | 18 Years | N/A | All | 12 | Phase 2 | Canada |
2 | NCT01307462 (ClinicalTrials.gov) | June 2011 | 1/3/2011 | Targeted Therapy of Bronchiolitis Obliterans Syndrome | Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant | Bronchiolitis Obliterans | Drug: fluticasone propionate;Drug: montelukast sodium;Drug: azithromycin | Stephanie Lee | National Cancer Institute (NCI) | Completed | 6 Years | 99 Years | All | 36 | Phase 2 | United States |
3 | NCT01211509 (ClinicalTrials.gov) | October 2010 | 28/9/2010 | Montelukast in Bronchiolitis Obliterans Syndrome | A Randomized, Double Blind, Placebo Controlled Trial With Montelukast to Treat Bronchiolitis Obliterans Syndrome After Lung Transplantation | Bronchiolitis Obliterans;Lung Transplantation;Graft Rejection | Drug: Montelukast | Universitaire Ziekenhuizen Leuven | Katholieke Universiteit Leuven | Completed | 18 Years | 75 Years | Both | 30 | Phase 4 | Belgium |
4 | EUCTR2010-021983-14-BE (EUCTR) | 23/09/2010 | 02/09/2010 | A randomized placebo-controlled double blind study to treat BOS. | A randomized placebo-controlled double blind study to treat BOS. | -Mortality at 1 and 2 year post diagnosis of BOS-Infection rate during BOS-Evolution of pulmonary function after diagnosis of BOS MedDRA version: 12.1;Level: LLT;Classification code 10029888;Term: Obliterative bronchiolitis MedDRA version: 12.1;Classification code 10049202;Term: Bronchiolitis obliterans MedDRA version: 12.1;Classification code 10068805;Term: Follicular bronchiolitis MedDRA version: 12.1;Classification code 10019319;Term: Heart-lung transplant rejection MedDRA version: 12.1;Classification code 10025127;Term: Lung transplant MedDRA version: 12.1;Classification code 10051604;Term: Lung transplant rejection MedDRA version: 12.1;Classification code 10056409;Term: Heart and lung transplant MedDRA version: 12.1;Classification code 10016547;Term: FEV MedDRA version: 12.1;Classification code 10016549;Term: FEV 1 abnormal MedDRA version: 12.1;Classification code 10016550;Term: FEV 1 decreased MedDRA version: 12.1;Classification code 10016553;Term: FEV 1 low | Trade Name: Montelukast Teva Product Name: montelukast teva Product Code: NA INN or Proposed INN: MONTELUKAST SODIUM Other descriptive name: Singulair | UZ Gasthuisberg | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Belgium | |||
5 | NCT00656058 (ClinicalTrials.gov) | June 17, 2008 | 9/4/2008 | Montelukast to Treat Bronchiolitis Obliterans | Multi-Institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic or Autologous Stem Cell Transplantation in Children and Adults | Bronchiolitis Obliterans;Chronic Graft Versus Host Disease;Leukotriene;Montelukast;Stem Cell Transplant | Drug: Singulair (Montelukast Sodium) | National Cancer Institute (NCI) | NULL | Completed | 6 Years | 80 Years | All | 25 | Phase 2 | United States |